Purchase of the first 90%, 231 hospitals commonly used drugs will carry out with volume procurement!

On October 9th, Anhui Province's centralized pharmaceutical procurement platform issued a notice on soliciting and negotiating the price of clinically commonly used drugs in public medical institutions in Anhui Province in 2020 (hereinafter referred to as the "Draft for Comments"), which will negotiate the price of four types of drugs for clinically commonly used respiratory drugs, acid suppressants, liver and bile diseases, and medical imaging contrast agents.
these drugs will be selected in 2019 accounted for the province's public medical institutions in the first four categories of procurement of 90% of the products, and combined with clinical practical organization experts to select and determine.
rounds of negotiations to form a volume procurement final price for enterprises more concerned about the shortlist rules, Anhui in the draft for comments to elaborate.
according to the negotiation process, Anhui will first let the enterprise confirm the product agreed by experts shortlist price, if the enterprise does not accept this price, will not accept the product negotiations.
However, the draft does not explain the formation mechanism of the product shortlist price, in the industry's view, this price may be corresponding to the product has a certain volume of historically low actual transaction price, this first threshold or will directly lead to some enterprises to take the lead out.
the products to be negotiated will be included in the corresponding product competition group on the basis of expert argumentation, and as can be seen from the grouping, respiratory drug use will undoubtedly be the most competitive group, with as many as 88 drugs to be negotiated in its four competitive combinations.
after the completion of the grouping, the company will report the decrease by product and fill in the "Negotiating Voluntary Price Reduction Commitment Letter" to determine the negotiated benchmark price (product negotiation benchmark price×.
Specific groups and total number of drugs (the number of drugs in each group later according to the enterprise confirmation of the final price adjustment) immediately followed, Anhui will be based on the competition group effectively declare the number of products, combined with the product declaration decline from large to small order of elimination, determine the negotiation of drugs and enterprises.
the smallest amount of online purchases in the province in 2019 will be eliminated when the smallest reduction in the number of filings occurs.
or out of clinical objective patient demand considerations, Anhui phase-out mechanism is not radical, giving pharmaceutical companies a certain amount of room for price reduction.
, on the basis of the negotiated benchmark price, the shortlisted products will continue to negotiate with the Group of Experts after two rounds of negotiations, which were successful before the formation of a volume procurement negotiating price.
draft for comments, the volume purchase negotiation price is the actual supply price of the enterprise, should include taxes, distribution fees and other costs.
the accelerated exploration of local belt procurement in the context of the third batch of national drug centralized belt procurement is about to land, provincial and local drug belt procurement is also accelerating exploration.
In addition to Anhui, Guangxi recently officially released the province's pharmaceutical group procurement (second batch) procurement list of products, covering cephalosporine sodium Shubatan sodium, pyrithrin sodium Shubatan sodium, Orasitan and other 100 varieties.
note that the main force on the list is still a small number of injections, the number of varieties as many as 84.
addition to all public medical and health institutions that have joined the drug procurement group, Guangxi also encourages medical insurance designated social medical institutions and retail pharmacies to participate.
The inter-provincial procurement alliance, composed of six provinces and two districts, including Sichuan, Shanxi, Inner Mongolia, Liaoning, Jilin, Heilongjiang, Hainan and Tibet, also issued a paper, deciding to carry out the 2020 provincial alliance drug centralized belt procurement work, involving quiculding injections, seven-leaf soap There are 17 drugs, such as nicotine injections, nicotine injections, renitide injections, medazole silo injections, cyclophosphate glucosamine injections, etc., and the specific agreed procurement volume, procurement methods and procurement requirements have yet to be further confirmed.
the four cities of Linyi, Zhanzhuang, Jining and Luze in Shandong Province formed the Lunan Economic Circle Procurement Alliance, which implemented the price linkage of centralized procurement results in the province from October 1.
According to the "Lunan Economic Circle Public Medical Institutions Drug (Supplies) Procurement Alliance on promoting the central procurement of municipal drugs (supplies) policy linkage notice", according to the four municipal health insurance bureaus jointly issued the drug (consumables) collection results carried out by other local and municipal alliances in Shandong Province, by the Lunan Economic Circle Alliance City Procurement Federation joint research identified the linked products, the Alliance City public medical institutions with products not less than 50% of the annual use of the standard.
note that the Lunan Economic Circle Procurement Alliance will also push for lower prices for related products.
In accordance with the requirements of the four cities, the previous Shandong Province, the municipal band volume of the purchase of varieties, when there are other unelolished manufacturers in the hospital in the case of products, should be in accordance with the province's mainland municipal collection selected product prices and payment standards, bargaining with manufacturers to ensure that the products retained for use at a reasonable price level.
If the manufacturers of in-house varieties do not agree to reduce prices, the member units of the purchasing union will replace 1-2 kinds of linked products according to the selected product specifications, quality, model, industry concentration, clinical use requirements and other factors.
medical institutions equipped with similar products to reach 2 or more, the lowest price of the annual share of the product is not less than 40%.
drug belt procurement has gradually become the new normal of the pharmaceutical industry, for participating pharmaceutical enterprises, as soon as possible familiar with the local recruitment rules and entry conditions, in order to calmly cope with, to maximize benefits.
.